Bioviz Technologies
Biosimilar developer, India. 1 development product across 1 molecule: epoetin alfa and zeta.
First approval in the Atlas: Aug 2011, Bioviz Technologies (INN only), epoetin alfa and zeta (CDSCO)
FDAproducts approved0
EMAproducts approved0
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved1
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Epoetin alfa and zeta | Bioviz epoetin | · | · | · | · | Aug 2011 | · |
Month shown is the first approval or registration of that product in that market.
Chronology
- CDSCOAug 2011Bioviz Technologies (INN only), epoetin alfa and zeta
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.